Antisense Therapeutics Ltd (ASX: ANP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Antisense Therapeutics Ltd. Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $100.53 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 574.48 million
Earnings per share -0.007
Dividend per share N/A
Year To Date Return 38.46%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Antisense Therapeutics Ltd (ASX: ANP)
Latest News

ANP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Antisense Therapeutics Ltd

Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals.

ANP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 Sep 2021 $0.18 $-0.01 -5.56% 104,280 $0.18 $0.18 $0.18
15 Sep 2021 $0.18 $0.00 0.00% 210,888 $0.18 $0.18 $0.18
14 Sep 2021 $0.18 $-0.01 -5.41% 753,299 $0.18 $0.19 $0.18
13 Sep 2021 $0.19 $0.01 5.71% 1,092,393 $0.19 $0.19 $0.18
10 Sep 2021 $0.18 $0.00 0.00% 701,842 $0.18 $0.19 $0.17
09 Sep 2021 $0.18 $-0.01 -5.41% 635,139 $0.18 $0.18 $0.18
08 Sep 2021 $0.19 $0.02 11.76% 367,739 $0.18 $0.19 $0.18
07 Sep 2021 $0.17 $-0.01 -5.56% 1,478,032 $0.18 $0.19 $0.17
06 Sep 2021 $0.18 $-0.01 -5.41% 518,836 $0.19 $0.19 $0.18
03 Sep 2021 $0.19 $-0.01 -5.26% 260,217 $0.19 $0.19 $0.19
02 Sep 2021 $0.19 $0.01 5.41% 148,556 $0.19 $0.19 $0.19
01 Sep 2021 $0.19 $-0.01 -5.26% 266,404 $0.19 $0.19 $0.19
31 Aug 2021 $0.19 $0.00 0.00% 201,615 $0.20 $0.20 $0.19
30 Aug 2021 $0.19 $0.01 5.41% 1,972,551 $0.19 $0.20 $0.19
27 Aug 2021 $0.19 $0.02 11.76% 856,843 $0.18 $0.19 $0.18
26 Aug 2021 $0.17 $0.00 0.00% 361,477 $0.17 $0.18 $0.17
25 Aug 2021 $0.17 $-0.01 -5.56% 241,254 $0.18 $0.18 $0.17
24 Aug 2021 $0.18 $0.01 5.88% 481,476 $0.18 $0.18 $0.18
23 Aug 2021 $0.17 $0.01 6.06% 361,890 $0.17 $0.18 $0.17
20 Aug 2021 $0.17 $-0.01 -5.71% 909,071 $0.18 $0.18 $0.17
19 Aug 2021 $0.18 $-0.01 -5.56% 498,175 $0.18 $0.18 $0.18
18 Aug 2021 $0.18 $0.01 5.88% 1,037,718 $0.18 $0.18 $0.18
17 Aug 2021 $0.17 $0.01 6.06% 778,114 $0.17 $0.18 $0.17

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Dec 2020 Robert Moses Issued 90 $9,020
Participation in share purchase plan.
02 Dec 2020 Mark Diamond Issued 180 $18,040
Participation in share purchase plan.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Professor Graham Mitchell Non-Executive Director Oct 2001
Professor Mitchell was a former senior researcher at the Walter & Eliza Hall Institute, a Chief Scientist in Victorian Government Departments, and a Director of Research in the R&D Division of CSL Limited. He is currently Principal and CEO of Foursight Associates Pty Ltd.
Dr Gary W Pace Non-Executive Director Nov 2015
Dr Pace has more than 40 years of experience in the development and commercialization of technologies in biotechnology, pharmaceuticals, medical devices and the food industries. He has held visiting academic positions at the Massachusetts Institute of Technology and the University of Queensland. Dr Pace is currently a director of Pacira Pharmaceuticals Inc.
Mr Robert William Moses Non-Executive Director Oct 2001
Mr Moses was formerly Corporate Vice President of CSL Limited. Mr Moses has more than 40 years experience in the pharmaceutical/ biotechnology industry. During the period 1993-2001, he played a role in CSL's development internationally. Prior to CSL, he was Managing Director of commercial law firm Freehills, Chairman and CEO of medical service company, and Corporate Manager of New Business Development at ICI (now Orica). Mr Moses is also the former Non-Executive Chairman of TGR Biosciences Pty Ltd and also has had spend 17 years in management roles at the pharmaceutical company Eli Lilly.
Mr Mark P Diamond Chief Executive OfficerManaging Director Oct 2001
Mr Diamond has over 30 years experience in the pharmaceutical and biotechnology industry. Previously, Mr Diamond was serving in US as Director, Project Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding's European operation based in the UK and Business Development Manager with Faulding in Australia.
Mr William Goolsbee Non-Executive Director Oct 2015
Mr Goolsbee was founder, Chairman and Chief Executive Officer of Horizon Medical Inc. from 1987 until its acquisition by a unit of UBS Private Equity in 2002. Mr Goolsbee was a founder & Director of ImmunoTherapy Corporation in 1993, and became Chairman in 1995, a position he held until overseeing the successful acquisition of ImmunoTherapy by AVI Biopharma, Inc. (now Sarepta Therapeutics) in 1998. Mr Goolsbee served as Chairman of privately held BMG Pharma LLC from 2006 through 2011 and of Metrodora Therapeutics until 2015. He currently serves as an Director of Helix BioMedix, Inc. (Since 2019) and previously a director of Sarepta Therapeutics Inc (Until December 2016).
Dr Charmaine Gittleson Non-Executive DirectorNon-Executive Chairman Mar 2021
Dr Gittleson is a senior executive with international experience as a pharmaceutical physician and enterprise manager in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company CSL Limited (ASX: CSL). During her time at CSL, Dr Gittleson had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, providing leadership in strategic product development, planning and implementation across multiple therapeutic and rare disease areas. At CSL, Dr Gittleson held a range of leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical Officer in Melbourne from 2017 until her recent retirement from corporate roles in 2020. Dr Gittleson was Chair of the company's Global Benefit Risk Committee, managing overall product safety which facilitated regulatory approvals in USA, EU, Japan, South America and Asia-Pacific; Chair of CSL's Bioethics Advisory Forum; and Chair of CSL's Strategic and Technical Risk Committee, tasked with delivering development programs on time with quality and within budget, achieving five new global product approvals and launches within a 24-month period, which included a number of rare disease therapies. In her role as Senior Vice President Clinical Development, Dr Gittleson led all clinical and safety strategic and operational R&D functions with teams in USA, Europe, Japan, China and Australia and was responsible for managing an annual clinical development budget and was a participant in regulatory agency negotiations, due diligence activities, industry meetings and annual analyst briefings. Dr Gittleson has been a scientific speaker at multiple medical conferences and regulatory workshops (FDA and EMA) and a keynote speaker at Women in Pharma & Leadership conferences for Women in ASX200 listed companies 2017, 2018 and 2019.
Mr Phillip Hains Joint Company Secretary Nov 2006
-
Ms Alicia Mellors Joint Company Secretary Feb 2021
-
Nuket Desem Director Clinical & Regulatory Affairs
-
George Tachas Director Drug Discovery & Patents
-
Alicia Mellors Joint Company Secretary
-
Phillip Hains Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited 26,310,597 5.38%
Hsbc Custody Nominees (Australia) Limited 25,510,561 5.22%
J P Morgan Nominees Australia Pty Limited 11,269,099 2.30%
Citycastle Pty Ltd 10,293,620 2.11%
Mutual Investments Pty Ltd <Mitchell Family A/C> 10,000,000 2.05%
Citicorp Nominees Pty Limited 9,899,065 2.02%
Esarad Holdings Pty Ltd 9,500,000 1.94%
Mr Robert William Moses 9,000,000 1.84%
Citycastle Pty Ltd i 8,747,369 1.79%
Altor Capital Management Pty Ltd <Altor Alpha Fund A/C> 8,600,000 1.76%
Mr Robertson Mclennan Mitchell & Mrs Karen Joy Mitchell 7,100,000 1.45%
Xcelerate Trading Pty Ltd <Xcelerate Trading A/C> 5,948,298 1.22%
Shared Office Services Pty Ltd <Philanne S/F A/C> 5,940,602 1.21%
Sked Pty Ltd <Super Fund A/C> 5,362,289 1.10%
Mr Raymond Laurence Carroll 5,000,000 1.02%
Jamplat Pty Ltd 5,000,000 1.02%
Mr Mark Diamond 4,242,772 0.87%
Bayspec Pty Ltd 4,000,001 0.82%
Mr David Kenley 4,000,000 0.82%
Statemoor Pty Ltd <Peters Family A/C> 3,821,034 0.78%

Profile

since

Note